Intellia Therapeutics' One-Time HAE Therapy Cuts Attacks 87% in Trial as FDA Decision Nears
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Intellia: Quiet Q3 Earnings As All Eyes Turn To March 2027 Approval Decision
Loading...